UNICANCER
- Country
- 🇧🇷Brazil
- Ownership
- Private
- Established
- 1964-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.unicancer.fr
A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas
- Conditions
- Interventions
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 163
- Registration Number
- NCT02389244
- Locations
- 🇫🇷
Hopital Jean Monjoz, Besancon, France
🇫🇷Institut Bergonie, Bordeaux, France
🇫🇷Centre Francois Baclesse, Caen, France
Study of Gemcitabine+Platinum Salt+Bevacizumab Combination for Metastatic Collecting Duct Carcinoma (GETUG-AFU 24)
- First Posted Date
- 2015-02-16
- Last Posted Date
- 2021-03-09
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 36
- Registration Number
- NCT02363751
- Locations
- 🇫🇷
Institut de Cancérologie de l'Ouest-Site Paul Papin, Angers, France
🇫🇷CHU Besançon, Besançon, France
🇫🇷Centre François Baclesse, Caen, France
Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status
- Conditions
- Interventions
- First Posted Date
- 2015-01-15
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 86
- Registration Number
- NCT02339532
- Locations
- 🇫🇷
Centre Paul Strauss, Strasbourg, France
🇫🇷Institut de Cancerologie de L'Ouest - Site Paul Papin, Angers, France
🇫🇷Centre Hospitalier Regional Universitaire de Brest - Hôpital Morvan, Brest, France
Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-12-24
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 174
- Registration Number
- NCT02324088
Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations
- Conditions
- Interventions
- First Posted Date
- 2014-12-02
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 216
- Registration Number
- NCT02304809
- Locations
- 🇫🇷
Tredaniel, Paris, France
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
- Conditions
- Interventions
- Drug: AZD2014Drug: AnthracyclinesDrug: MEDI4736Drug: AZD4547Drug: TaxanesDrug: AZD5363Drug: cyclophosphamideDrug: DNA intercalatorsDrug: AZD8931Drug: SelumetinibDrug: MethotrexateDrug: vinca alkaloidsDrug: VandetanibDrug: Platinum based chemotherapiesDrug: BicalutamideDrug: OlaparibDrug: BevacizumabDrug: Mitomycin CDrug: Eribulin
- First Posted Date
- 2014-11-24
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 1460
- Registration Number
- NCT02299999
- Locations
- 🇫🇷
Hopitaux Universitaire de Strasbourg - Hopital Civil, Strasbourg, France
🇫🇷Institut Claudius Regaud, Toulouse, France
🇫🇷Hopitaux Du Leman, Thonon-les-Bains, France
SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients
- First Posted Date
- 2014-04-17
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 999
- Registration Number
- NCT02117167
- Locations
- 🇫🇷
Hôpital Avicenne, Bobigny, France
🇫🇷Institut Bergonié, Bordeaux, France
🇫🇷Institut Paoli Calmettes, Marseille, France
Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1
- Conditions
- Interventions
- First Posted Date
- 2014-01-14
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 246
- Registration Number
- NCT02034981
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Ile De France, France
Chronic Toxicities Related to Treatment in Patients With Localized Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 14750
- Registration Number
- NCT01993498
- Locations
- 🇫🇷
Gustave roussy, Villejuif, France
Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After Prostatectomy
- Conditions
- Interventions
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 120
- Registration Number
- NCT01994239
- Locations
- 🇫🇷
Hôpital Saint Louis, Paris, France
🇫🇷Clinique Sainte-Marguerite, Hyeres, France
🇫🇷Institut de Cancérologie de l'Ouest -Site Paul Papin, Angers, France